Summary from the GEO: " Even though urothelial cancer (UC) is the fourth common tumor type among males, progress in treatment development has been deficient. Pathological assessment provides the urologists with only a broad classification, complicated by frequent disagreement among pathologist and the co-existence of different grading systems. Consequently, there is a great need for an objective,...

This dataset contains summary data visualizations and clinical data from a broad sampling of 411 bladder urothelial carcinomas from 411 patients. The data was gathered as part of the PanCancer Atlas initiative, which aims to answer big, overarching questions about cancer by examining the full set of tumors characterized in the robust TCGA dataset. The clinical data includes mutation count, information...

Whole-exome and targeted sequencing of plasmacytoid bladder cancer, an aggressive histologic variant with a high risk of disease-specific mortality. This dataset contains summary data visualizations and sequencing data of 34 plasmacytoid-variant (signet ring cell) tumors of the bladder from 31 patients. Clinical data includes detailed cancer type, mutation count, information about mutated genes, patient...

This dataset contains summary data visualizations and clinical data for a list of oncogenic and likely oncogenic alterations in 413 samples in tumors of the bladder from 412 patients, gathered as part of a comprehensive molecular characterization of muscle-invasive bladder cancer. Clinical data includes mutation count, information about mutated genes, patient demographics, and American Joint Committee...

In this study, six plasmacytoid bladder cancers were analyzed by whole exome sequencing. The results show loss of the CDH1 gene in every sample and correlate with E-cadherin loss of expression by immunohistochemistry. A separate validation cohort of plasmacytoid samples showed loss of E-cadherin expression by CDH1 mutation or promoter hypermethylation. The data includes information about the study,...

Summary from the GEO: "RNA-sequencing of a panel of urothelial cancer cells. The goal of the study is to examine the genome-wide expression profile in each of the 30 urothelial cancer cells tested in our laboratory." "Overall design: Each of the 30 cell lines was DNA fingerprinted to confirm its real identity. Total RNA was obtained from each cell line and subjected to Illumina RNA sequencing."...

This dataset contains summary data visualizations and clinical data from the targeted sequencing of 10,000 clinical cases using the MSK-IMPACT assay. The clinical data includes mutation count, information about mutated genes, tumor mutational burden calculations, tissue site from which the sample was derived, tumor purity among other relevant data points. The data set also includes copy-number segment...

This dataset contains summary data visualizations and clinical data from a broad of 85 samples of upper tract urothelial carcinoma tumors from 83 patients. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes mutation count, information about mutated genes, patient demographics, disease status, Adjuvant Chemotherapy, American Joint Committee on Cancer...

This dataset contains summary data visualizations and clinical data from a broad sampling of upper tract unothelial carcinoma tumors. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, patient demographics, American Joint Committee...

This dataset contains summary data visualizations and clinical data from a broad sampling of HER2- and HER3-mutant tumors. The data was generated utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, Amplification Status, Best objective response rate, Bubble...